Efficacy and Safety of Alfuzosin for the Treatment of Voiding Dysfunction in Female
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the efficacy of Alfuzosin (10 mg, qd) in reducing the
score of International Prostate Symptom Score (IPSS) from baseline to 8 weeks of treatment in
female patients with voiding dysfunction.
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center
Collaborators:
Handok Inc. Handok Pharmaceuticals Co., Ltd. The Korean Urological Association